Folic acid and prevention of colorectal adenomas: a combined analysis of randomized clinical trials - PubMed (original) (raw)
. 2011 Jul 1;129(1):192-203.
doi: 10.1002/ijc.25872. Epub 2011 Apr 1.
Affiliations
- PMID: 21170989
- PMCID: PMC3753215
- DOI: 10.1002/ijc.25872
Folic acid and prevention of colorectal adenomas: a combined analysis of randomized clinical trials
Jane C Figueiredo et al. Int J Cancer. 2011.
Abstract
Observational data suggest that lower folate status is associated with an increased risk of colorectal neoplasia, implying that folate may be useful as a chemopreventive agent. We conducted a combined analysis of three large randomized trials of folic acid supplementation for the prevention of metachronous adenomas in patients with an adenoma history. Participants included 2,632 men and women who had a history of adenomas randomized to either 0.5 or 1.0 mg/day of folic acid or placebo and who had a follow-up endoscopy 6 to 42 months after randomization [mean = 30.6 (standard deviation = 8.1) months]. We used random-effects meta-analysis to estimate risk ratios (RRs) and 95% confidence intervals (CIs). The RR comparing folic acid versus placebo was 0.98 (95% CI = 0.82-1.17) for all adenomas and 1.06 (95% CI = 0.81-1.39) for advanced lesions. Folic acid was associated with a nonsignificant decreased risk of any adenoma among subjects in the lowest quartile of baseline plasma folate (≤ 11 nmol/L) and no effect among individuals in the highest quartile (> 29 nmol/L, p for trend = 0.17). There was a nonsignificant trend of decreasing risk of any adenoma associated with folic acid supplements with increasing alcohol intake. During the early follow-up reported here, more deaths occurred in the placebo group than in the folic acid group (1.7% vs. 0.5%, p = 0.002). In conclusion, after up to 3.5 years of folic acid use, there is no clear decrease or increase in the occurrence of new adenomas in patients with a history of adenoma.
Copyright © 2010 UICC.
Figures
Figure 1
Random-effects meta-analysis comparing folic acid versus placebo after a follow-up of 42 months. Estimates are unadjusted. Tests for heterogeneity are as follows: For any adenoma, _Q_=3.34 (_P_=0.19) and _I_2=70.0. For advanced lesion, _Q_=2.04 (_P_=0.36) and _I_2=2.0. AFPPS, Aspirin/Folate Polyp Prevention Study; NHS/HPFS, Nurses’ Health Study/Health Professional Follow-up Study; ukCAP, United Kingdom Colorectal Adenoma Prevention.
Figure 2
Random-effects meta-analysis comparing folic acid versus placebo for the endpoints of 3 or more adenomas, adenomas greater than or equal to 1 cm in estimated diameter and location in the colorectum. Estimates are unadjusted. Tests for heterogeneity are as follows: For >=3 adenomas, _Q_=0.99 (_P_=0.61) and _I_2=0.0; adenomas >= 1cm, _Q_=2.30 (_P_=0.32) and _I_2=13.0; rectal adenoma Q=2.19 (_P_=0.33) and _I_2=8.7; distal adenoma Q=5.32 (_P_=0.70) and _I_2=62.4 proximal adenoma Q=3.09 (_P_=0.21) and _I_2=35.3. Proximal adenomas include those in the transverse colon, hepatic flexure, ascending colon and cecum; distal adenomas include those in the sigmoid colon, descending colon and splenic flexure. AFPPS, Aspirin/Folate Polyp Prevention Study; NHS/HPFS, Nurses’ Health Study/Health Professional Follow-up Study; ukCAP, United Kingdom Colorectal Adenoma Prevention.
Figure 3
Random-effects meta-analysis comparing folic versus placebo by subgroups (all exams) for any adenoma. Estimates are unadjusted. P values are from tests for heterogeneity between groups for categorical variables (sex, family history of colorectal cancer, number of adenomas at baseline, advanced lesion at baseline, and aspirin treatment) and tests for trend for ordinal variables (age, BMI, smoking status, alcohol, dietary folate and plasma folate). Analysis of aspirin treatment group was restricted to the AFPPS and ukCAP trials and the analysis of plasma folate was restricted to the AFPPS and NHS/HPFS trials. AFPPS, Aspirin/Folate Polyp Prevention Study; NHS/HPFS, Nurses’ Health Study/Health Professional Follow-up Study; ukCAP, United Kingdom Colorectal Adenoma Prevention.
Figure 4
Random-effects meta-analysis comparing folic acid versus placebo by subgroups (all exams) for advanced adenoma. Estimates are unadjusted. P values are from tests for heterogeneity between groups for categorical variables (sex, family history of colorectal cancer, number of adenomas at baseline, advanced lesion at baseline, and aspirin treatment) and tests for trend for ordinal variables (age, BMI, smoking status, alcohol, dietary folate and plasma folate). Analysis of aspirin treatment group was restricted to the AFPPS and ukCAP trials and the analysis of plasma folate was restricted to the AFPPS and NHS/HPFS trials. AFPPS, Aspirin/Folate Polyp Prevention Study; NHS/HPFS, Nurses’ Health Study/Health Professional Follow-up Study; ukCAP, United Kingdom Colorectal Adenoma Prevention.
Similar articles
- Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group. Cole BF, et al. JAMA. 2007 Jun 6;297(21):2351-9. doi: 10.1001/jama.297.21.2351. JAMA. 2007. PMID: 17551129 Clinical Trial. - Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Figueiredo JC, Levine AJ, Grau MV, Midttun O, Ueland PM, Ahnen DJ, Barry EL, Tsang S, Munroe D, Ali I, Haile RW, Sandler RS, Baron JA. Figueiredo JC, et al. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2136-45. doi: 10.1158/1055-9965.EPI-07-2895. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18708408 Free PMC article. Clinical Trial. - Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels.
Figueiredo JC, Levine AJ, Grau MV, Barry EL, Ueland PM, Ahnen DJ, Byers T, Bresalier RS, Summers RW, Bond J, McKeown-Eyssen GE, Sandler RS, Haile RW, Baron JA. Figueiredo JC, et al. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2625-31. doi: 10.1158/1055-9965.EPI-08-0382. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18843003 Free PMC article. Clinical Trial. - Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P. Cooper K, et al. Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Health Technol Assess. 2010. PMID: 20594533 Review. - [Folic acid supplementation and colorrectal adenoma recurrence: systematic review].
Castillo-Lancellotti C, Tur Marí JA, Uauy Dagach R. Castillo-Lancellotti C, et al. Nutr Hosp. 2012 Jan-Feb;27(1):13-21. doi: 10.1590/S0212-16112012000100003. Nutr Hosp. 2012. PMID: 22566300 Review. Spanish.
Cited by
- Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis.
Fu Q, Liao H, Li Z, Chen X, Zhang X, Di J. Fu Q, et al. Arch Med Sci. 2023 Jun 21;19(5):1428-1445. doi: 10.5114/aoms/167480. eCollection 2023. Arch Med Sci. 2023. PMID: 37732038 Free PMC article. Review. - Dietary Intervention for Preventing Colorectal Cancer: A Practical Guide for Physicians.
Kim SH, Moon JY, Lim YJ. Kim SH, et al. J Cancer Prev. 2022 Sep 30;27(3):139-146. doi: 10.15430/JCP.2022.27.3.139. J Cancer Prev. 2022. PMID: 36258718 Free PMC article. Review. - The relationship between folic acid and colorectal cancer; a literature review.
Kherbek H, Daoud R, Soueycatt T, Soueycatt Y, Ali Z, Ehsan J, Alshehabi Z, Georgeos M. Kherbek H, et al. Ann Med Surg (Lond). 2022 Jul 12;80:104170. doi: 10.1016/j.amsu.2022.104170. eCollection 2022 Aug. Ann Med Surg (Lond). 2022. PMID: 35855881 Free PMC article. Review. - Folates, folic acid and preconception care - a review.
House SH, Nichols JA, Rae S. House SH, et al. JRSM Open. 2021 May 13;12(5):2054270420980875. doi: 10.1177/2054270420980875. eCollection 2021 May. JRSM Open. 2021. PMID: 34035929 Free PMC article. Review. - Association of folate intake and colorectal cancer risk in the postfortification era in US women.
Wang F, Wu K, Li Y, Song R, Wu Y, Zhang X, Song M, Liang L, Smith-Warner SA, Giovannucci EL, Willett WC. Wang F, et al. Am J Clin Nutr. 2021 Jul 1;114(1):49-58. doi: 10.1093/ajcn/nqab035. Am J Clin Nutr. 2021. PMID: 33742202 Free PMC article.
References
- Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132:2350S–5S. - PubMed
- Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005;113:825–8. - PubMed
- Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16:1325–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA095589/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA 67883/CA/NCI NIH HHS/United States
- CA95589/CA/NCI NIH HHS/United States
- R01 CA059005/CA/NCI NIH HHS/United States
- N01-CO-12400/CO/NCI NIH HHS/United States
- U54-CA-100971/CA/NCI NIH HHS/United States
- R01-CA-059005/CA/NCI NIH HHS/United States
- CA 55075/CA/NCI NIH HHS/United States
- U54 CA100971/CA/NCI NIH HHS/United States
- N01CO12400/CA/NCI NIH HHS/United States
- R01 CA067883/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical